Breast最新文献

{"title":"Factors associated with breast lymphedema after adjuvant radiation therapy in women undergoing breast conservation therapy","authors":"Summer Sami Yono ,&nbsp;Cara Cannella ,&nbsp;Madeleine Gonte ,&nbsp;Sanjay Rama ,&nbsp;Simeng Zhu ,&nbsp;Jenna Luker ,&nbsp;Maristella S. Evangelista ,&nbsp;Jessica Bensenhaver ,&nbsp;Eleanor M. Walker ,&nbsp;Dunya Atisha","doi":"10.1016/j.breast.2024.103846","DOIUrl":"10.1016/j.breast.2024.103846","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast lymphedema after post-lumpectomy radiation therapy (RT) is poorly defined and difficult to treat. The aim of this study was to define the incidence of breast lymphedema and identify factors associated with the risk of developing breast lymphedema (BL) in women undergoing breast-conserving therapy.</div></div><div><h3>Methods</h3><div>A retrospective cohort study of patients with early-stage breast cancer who underwent breast-conserving surgery (lumpectomy) followed by RT between January 1, 2014 and July 31, 2019 at a single institution. Women who developed BL, defined as swelling of the breast persisting ≥1 year after RT, were compared with women who did not. Univariate and multivariate regression analyses were used to identify factors associated with risk of BL.</div></div><div><h3>Results</h3><div>A total of 1052 patients were included in the study: 99 (9.6 %) developed BL and 953 (90.6 %) did not develop BL. The mean ± standard deviation age was 62.9 ± 11.1 years and the mean breast volume was 1352.0 ± 744.9 cm³. Patients with breast volume ≥1500 cm³ (adjusted odds ratio [aOR] = 2.34; 95 % CI, 1.40–3.91; <em>p</em> = 0.001), Black patients (aOR = 1.78; 95 % CI, 1.12–2.82; <em>p</em> = 0.015), those who received neoadjuvant (aOR = 3.05; 95 % CI, 1.28–7.30; <em>p</em> = 0.012) or adjuvant chemotherapy (aOR = 2.14; 95 % CI, 1.29–3.55; <em>p</em> = 0.003), those with postoperative cellulitis (aOR = 3.94; 95 % CI, 2.20–7.06; <em>p</em> &lt; 0.001), and women who developed arm lymphedema (aOR = 2.94; 95 % CI, 1.50–5.77; <em>p</em> = 0.002) had significantly higher odds of developing BL.</div></div><div><h3>Conclusion</h3><div>Patients with larger breast volumes, Black patients, those receiving chemotherapy, and those who develop arm lymphedema or cellulitis may be at higher risk of BL after lumpectomy and RT, suggesting that patients with these risk features may benefit from complementary or alternative surgical approaches and heightened monitoring to avoid BL.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103846"},"PeriodicalIF":5.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of oligometastatic breast cancer: The role of patient selection","authors":"Riccardo Ray Colciago ,&nbsp;Maria Carmen De Santis ,&nbsp;Carlotta Giandini ,&nbsp;Maria Grazia Carnevale ,&nbsp;Serena Di Cosimo","doi":"10.1016/j.breast.2024.103839","DOIUrl":"10.1016/j.breast.2024.103839","url":null,"abstract":"<div><div>Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT). This has become a valid ablative treatment option for OMD patients.</div><div>However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients. We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103839"},"PeriodicalIF":5.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects","authors":"Yufei Wang ,&nbsp;Guangliang Li ,&nbsp;Hanying Wang ,&nbsp;Quan Qi ,&nbsp;Xian Wang ,&nbsp;Haiqi Lu","doi":"10.1016/j.breast.2024.103838","DOIUrl":"10.1016/j.breast.2024.103838","url":null,"abstract":"<div><div>Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, which has been approved by FDA for the treatment of urothelial carcinoma. Notably, Nectin-4 was also investigated as a target for breast cancer in preclinical and clinical settings. Nectin-4-targeted approaches, such as ADCs, oncolytic viruses, photothermal therapy and immunotherapy, have shown promising results in early-phase clinical trials. These therapies offer novel strategies for delivering targeted treatments to Nectin-4-expressing cancer cells, enhancing treatment efficacy and minimizing off-target effects. In conclusion, this review aims to provide an overview of the latest advances in understanding the role of Nectin-4 in breast cancer and discuss the future development prospects of Nectin-4 targeted agents.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103838"},"PeriodicalIF":5.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050","authors":"Mengxia Fu ,&nbsp;Zhiming Peng ,&nbsp;Min Wu ,&nbsp;Dapeng Lv ,&nbsp;Yanping Li ,&nbsp;Shuzhen Lyu","doi":"10.1016/j.breast.2024.103835","DOIUrl":"10.1016/j.breast.2024.103835","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer remains a significant health concern in Asia. This study seeks to analyze the burden of breast cancer in Asia based on the most recent GLOBOCAN 2022 estimates.</div></div><div><h3>Methods</h3><div>Data were obtained from GLOBOCAN 2022. Age-standardized rates for incidence and mortality per 100,000 person-years were calculated using direct age standardization with the Segi-Doll World standard population. Pearson's correlation coefficient was utilized to evaluate the relationship between human development index and incidence or mortality rate. The future number of breast cancer cases and deaths by 2050 was estimated based on global demographic projections.</div></div><div><h3>Results</h3><div>In 2022, breast cancer accounted for 2296.8 thousand new cases and 666.1 thousand deaths worldwide. In Asia, an estimated 985.4 thousand new cases and 315.1 thousand deaths were reported, corresponding to age-standardized incidence and mortality rates of 34.3 and 10.5 per 100,000, respectively. Both incidence and mortality rates were notably higher among older individuals, especially in countries with high human development index. A positive correlation between human development index and incidence rates was observed, while mortality rates were highest in countries with low human development index. China and India are the leading contributors to both new cases and deaths, with projections indicating that by 2050, around 1.4 million new breast cancer cases and 0.5 million deaths are expected to occur in Asia.</div></div><div><h3>Conclusion</h3><div>Breast cancer is the most common cancer among women in Asia. Global collaboration is essential to reduce its growing burden, especially in low-HDI countries facing rising incidence and high mortality rates.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103835"},"PeriodicalIF":5.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis","authors":"Roberto Buonaiuto ,&nbsp;Aldo Caltavituro ,&nbsp;Margherita Tafuro ,&nbsp;Alessandra Longobardi ,&nbsp;Giuliana Pavone ,&nbsp;Pierluigi De Santis ,&nbsp;Roberta Caputo ,&nbsp;Carmine De Angelis ,&nbsp;Lucia Del Mastro ,&nbsp;Fabio Puglisi ,&nbsp;Mario Giuliano ,&nbsp;Grazia Arpino ,&nbsp;Martina Pagliuca ,&nbsp;Michelino De Laurentiis","doi":"10.1016/j.breast.2024.103833","DOIUrl":"10.1016/j.breast.2024.103833","url":null,"abstract":"<div><h3>Background</h3><div>The combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC). While the efficacy and safety profiles of CDK4/6i and ET have been extensively evaluated in phase II and III trials worldwide, it remains unclear whether the response to CDK4/6i and toxicity profile vary among Asian and non-Asian patients. Therefore, we aimed to assess the treatment efficacy of ET with and without CDK4/6i by comparing outcomes in Asian and non-Asian subgroups included in these clinical trials. In addition, we evaluated the toxicity profiles of the treatments by estimating the risk of treatment-related adverse events (AEs).</div></div><div><h3>Methods</h3><div>We conducted a meta-analysis including the most recent randomized trial data systematically searched from PubMed, Embase, Web of Science, Cochrane CENTRAL (from inception to May 31st, 2024) or presented in abstracts or oral presentations at the ESMO, ASCO, and SABCS international congresses. We included studies comparing CDK4/6i (palbociclib, ribociclib, abemaciclib, dalpiciclib) + ET versus placebo + ET. Progression-free survival (PFS) and overall survival (OS), hazard ratios (HR), and 95 % confidence intervals (CI) were extracted for the two subgroups of interest. To evaluate the treatment-related toxicity profiles, we extracted the number of side effects to estimate the risk of treatment-emergent AEs.</div></div><div><h3>Results</h3><div>Eleven studies (n = 5129) were included in this meta-analysis. The addition of CDK4/6i to ET consistently improved PFS in both Asian (HR = 0.52, 95 % CI 0.47–0.60; p &lt; 0.001) and non-Asian (HR = 0.58, 95 % CI 0.52–0.64; p &lt; 0.001) groups. Similarly, the combination of CDK4/6i + ET led to an OS improvement in both Asian (HR = 0.75, 95 % CI 0.62–0.91; p = 0.003) and non-Asian (HR = 0.81, 95 % CI 0.73–0.89; p &lt; 0.001) patients. The risk of treatment related toxicity was higher in the CDK4/6i + ET arm in both Asian and non-Asian groups. Interestingly, a numerically higher rate of treatment-related hematological toxicity was observed in Asian patients, although no significant interethnic difference was found in the relative risk of these events.</div></div><div><h3>Conclusions</h3><div>The combination of CDK4/6i and ET significantly improves PFS and OS compared to ET alone in both Asian and non-Asian patients with HR+/HER2-aBC. Although the magnitude of benefit appears to be independent of ethnicity, future clinical trials should devise a standardized method for stratifying patients by ethnicity to more effectively assess potential differences in treatment benefits.</div></div><div><h3>Systematic review registration</h3><div>PROSPERO registration number: CRD42024543217.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103833"},"PeriodicalIF":5.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study","authors":"Alfonso Cortés ,&nbsp;Elena López-Miranda ,&nbsp;Adela Fernández-Ortega ,&nbsp;Vicente Carañana ,&nbsp;Sonia Servitja ,&nbsp;Ander Urruticoechea ,&nbsp;Laura Lema-Roso ,&nbsp;Antonia Márquez ,&nbsp;Alexandros Lazaris ,&nbsp;Daniel Alcalá-López ,&nbsp;Leonardo Mina ,&nbsp;Petra Gener ,&nbsp;Jose Rodríguez-Morató ,&nbsp;Gabriele Antonarelli ,&nbsp;Antonio Llombart-Cussac ,&nbsp;José Pérez-García ,&nbsp;Javier Cortés","doi":"10.1016/j.breast.2024.103834","DOIUrl":"10.1016/j.breast.2024.103834","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline <em>BRCA1/2</em> mutations (g<em>BRCA1/2</em>mut).</div></div><div><h3>Methods</h3><div>NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC without <em>gBRCA1/2mut</em> and with HRD, who were treated with olaparib. The primary endpoint was clinical benefit rate (CBR) per RECIST v.1.1.</div></div><div><h3>Results</h3><div>Six of 114 patients were eligible and received olaparib. Median follow up was 8.5 months. CBR and overall response rate (ORR) were 50 % (95 % CI, 11.8–88.2).</div></div><div><h3>Conclusions</h3><div>The observed results could prompt further investigation.</div></div><div><h3>Trial</h3><div>ClinicalTrials.gov identifier NCT03367689.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103834"},"PeriodicalIF":5.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative reference values for breast cancer patients using the BREAST-Q","authors":"Charlotta Kuhlefelt ,&nbsp;Jussi P. Repo ,&nbsp;Veera Rasi ,&nbsp;Tuomo Meretoja ,&nbsp;Tiina Jahkola ,&nbsp;Susanna Kauhanen ,&nbsp;Pauliina Homsy","doi":"10.1016/j.breast.2024.103832","DOIUrl":"10.1016/j.breast.2024.103832","url":null,"abstract":"<div><h3>Introduction</h3><div>The BREAST-Q can be used to evaluate the health-related quality of life (HRQL) of breast cancer patients. Data interpretation is limited by the lack of previous reference values based solely on patients with a recent breast cancer diagnosis.</div></div><div><h3>Methods</h3><div>A total of 627 patients, all with newly diagnosed breast cancer, were asked to participate in the study. The BREAST-Q modules for mastectomy and breast-conserving surgery were used. The results for the scales were reported as mean with standard deviation (SD). The effect of patient characteristics, including age, body mass index (BMI), and ASA-classification on the HRQL were analyzed with multiple linear regression.</div></div><div><h3>Results</h3><div>In total, 315 patients (50.2 %) participated. The mean (SD) age was 60.3 (10.1) years. Mean scores (SD) were the following: Psychosocial Well-being 70.8 (15.0), Sexual Well-being 58.2 (15.1), Satisfaction with Breasts 59.9 (15.6), and Physical Well-being: Chest 81.7 (15.7). The psychosocial well-being, sexual well-being, and satisfaction with breasts were all similar compared to the normative mean scores of the scales. The physical well-being of the chest was lower than the normative mean value (p &lt; 0.001). Psychosocial well-being (p = 0.007), sexual well-being (p = 0.007), and satisfaction with breasts (p &lt; 0.001) were lower in patients with higher BMI. Younger patients reported lower physical well-being of the chest (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>This study established preoperative reference values for the BREAST-Q in breast cancer patients. This data can be used to evaluate the HRQL in breast cancer patients accurately.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103832"},"PeriodicalIF":5.7,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locoregional recurrence after neoadjuvant versus adjuvant chemotherapy based on tumor subtypes in patients with early-stage breast cancer: A multi-institutional retrospective cohort study","authors":"Jong-Ho Cheun ,&nbsp;Youngji Kwak ,&nbsp;Eunhye Kang ,&nbsp;Ji-Jung Jung ,&nbsp;Hong-Kyu Kim ,&nbsp;Han-Byoel Lee ,&nbsp;Kyung-Hun Lee ,&nbsp;Hyeong-Gon Moon ,&nbsp;Ki-Tae Hwang ,&nbsp;Yeon Hee Park ,&nbsp;Jeong Eon Lee ,&nbsp;Wonshik Han","doi":"10.1016/j.breast.2024.103828","DOIUrl":"10.1016/j.breast.2024.103828","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). We investigated whether the risk of LRR after NACT varies across tumor subtypes.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the medical records of women who underwent breast-conserving surgery for breast cancer at three institutions between January 1, 2004, and December 31, 2018. Patients received either NACT or adjuvant chemotherapy (ACT), followed by radiotherapy. LRR was analyzed according to the hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status using propensity score matching, log-rank test, and Cox regression analysis.</div></div><div><h3>Results</h3><div>Among 10,328 patients, 2479 (24.0 %) received NACT. Within the median follow-up of 84.5 (IQR, 35.1–118.5) months, the 10-year LRR-free survival rates were 94.5 % and 90.7 % for the ACT and NACT groups, respectively (hazard ratio: 2.04, 95 % confidence interval [CI]: 1.68–2.46, p &lt; 0.0001). NACT was significantly associated with higher LRR in the HR+/HER2− (hazard ratio: 2.52, 95 % CI: 1.83–3.46, p &lt; 0.0001) and HR−/HER2− (hazard ratio: 1.85, 95 % CI: 1.37–2.50, p &lt; 0.0001) subtypes. In the HR+/HER2− subtype, the elevated risk remained significant after propensity-score matching and Cox-regression analysis. However, NACT was not associated with LRR in the HR−/HER2− subtype after adjusting for other variables. Annual LRR pattern among the HR+/HER2− subtype showed the highest incidence in the early period of treatment.</div></div><div><h3>Conclusion</h3><div>Patients with the HR+/HER2− subtype showed an increased risk of LRR after NACT, while those with other subtypes showed comparable LRR-free survival.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103828"},"PeriodicalIF":5.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The “lows”: Update on ER-low and HER2-low breast cancer","authors":"Nicola Fusco ,&nbsp;Giuseppe Viale","doi":"10.1016/j.breast.2024.103831","DOIUrl":"10.1016/j.breast.2024.103831","url":null,"abstract":"<div><div>ER-low and HER2-low breast cancers have emerged as clinically significant subtypes that challenge traditional diagnostic categories and treatment paradigms. These subtypes, representing a spectrum of disease, exhibit distinct biological behaviors, therapeutic responses, and prognostic outcomes. HER2-low breast cancer, defined by low HER2 protein expression (IHC score of 1+ or 2+ without HER2 gene amplification), has achieved clinical significance, particularly following the DESTINY-Breast trials, which demonstrated the efficacy of trastuzumab deruxtecan (T-DXd) in the population of patients with advanced HER2-low disease. Similarly, ER-low breast cancer, characterized by low estrogen receptor expression (in 1%–10 % invasive tumor cells), poses unique challenges due to its intermediate biological behavior and uncertain response to endocrine therapies. The identification of these subtypes is further complicated by inconsistencies in testing methodologies, which can lead to misclassification and impact treatment decisions. As our understanding of these subtypes improves, the need for standardized diagnostic approaches and individualized therapeutic decisions becomes increasingly urgent. Ongoing research and collaboration between pathologists and oncologists are essential for refining diagnostic criteria and improving outcomes for patients with breast cancers characterized by low expression of these theragnostic biomarkers. This review aims to consolidate current knowledge on HER2-low and ER-low breast cancers, focusing on the challenges associated with their identification, the implications for treatment, and future directions in clinical management. By examining recent studies and interlaboratory assessments, this review emphasizes the critical need for accurate and reproducible testing and reporting, and for the development of tailored therapeutic strategies for these “low” expression cancers.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103831"},"PeriodicalIF":5.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes","authors":"Lu Sun ,&nbsp;Xiaomeng Jia ,&nbsp;Kainan Wang,&nbsp;Man Li","doi":"10.1016/j.breast.2024.103830","DOIUrl":"10.1016/j.breast.2024.103830","url":null,"abstract":"<div><div>Breast cancer has become the most prevalent malignant tumor worldwide and remains one of the leading causes of cancer-related mortality among women globally. The prognosis for patients with metastatic breast cancer remains poor, necessitating the exploration of novel therapeutic strategies to improve survival rates. In the era of precision medicine, antibody-drug conjugates (ADCs) have gained significant attention as a targeted therapeutic strategy in breast cancer treatment. ADCs, a relatively new treatment for breast cancer, deliver cytotoxic drugs (payloads), directly into the tumor space, turning chemotherapy into a targeted agent, which enables patients to experience significant improvements with manageable drug toxicity. For the treatment of breast cancer, there are three ADCs approved for breast cancer treatment: Trastuzumab emtansine (T-DM1), Trastuzumab Deruxtecan (T-Dxd) targeting HER-2, and Sacituzumab Govitecan (SG) targeting Trop-2. Recent clinical studies have demonstrated that the benefits of ADC therapies extend beyond HER2-positive breast cancer toinclude hormone receptor (HR)-positive breast cancer, triple-negative breast cancer (TNBC), and HER2-low expressing breast cancer. Notably, the DESTINY-Breast series of studies, particularly focusing on T-Dxd, encompass neoadjuvant, adjuvant, and multiple lines of therapy for advanced breast cancer. This marks the advent of a comprehensive ADC era in breast cancer treatment. This review summarizes the efficacy and adverse effects of ADC therapies that have completed or are currently undergoing phase I-III clinical trials. Additionally, it analyzes potential combination strategies to overcome ADC resistance, aiming to provide clinicians with a comprehensive clinical guide to the use of ADCs in breast cancer treatment.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103830"},"PeriodicalIF":5.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}